Suppr超能文献

伴有腺性分化的尿路上皮癌(UrAC)、原发性细支气管肺泡癌(BAC)及尿路上皮癌患者的生存情况。

Survival of Patients With UrAC and Primary BAC and Urothelial Carcinoma With Glandular Differentiation.

作者信息

Wang Tao, Lv Zheng, Feng Huayi, Li Jinlong, Cui Bo, Yang Yang, Huang Xing, Zhang Xiangyi, Li Xintao, Ma Xin

机构信息

Medical School of Chinese PLA, Beijing, China.

Department of Urology, The Third Medical Centre, Chinese PLA General Hospital, Beijing, China.

出版信息

Front Oncol. 2022 May 12;12:860133. doi: 10.3389/fonc.2022.860133. eCollection 2022.

Abstract

PURPOSE

To investigate the significance of demographic and pathological characteristics on the survival outcomes of urachal adenocarcinoma (UrAC), primary bladder adenocarcinoma (BAC) and urothelial carcinoma with glandular differentiation (UCGD) in China.

MATERIALS AND METHODS

We retrospectively analyzed cases with non-distant metastases (≤ T4M0). Of 106 patients, 30 (28.3%), 40 (37.7%), and 36 (34.0%) met the criteria for UrAC, primary BAC, and UCGD, respectively. Data on patient demographics, tumor pathology, and survival outcomes were collected. The median follow-up was 36 months. Survival was analyzed using multivariate Cox regression.

RESULTS

Patients with UrAC were younger (51.87 ± 15.25 years) than those with primary BAC (60.50 ± 12.56 years) and UCGD (63.83 ± 11.60 years) (<0.001). Patients with UrAC were the most likely to be stage T3-4 (70.0% . 40.0% . 44.4%; <0.001), while the primary BAC group had a higher rate of poor differentiation than the UrAC and UCGD groups (57.4% . 18.5% . 24.1%; <0.001). The Kaplan-Meier curves showed that the overall survival (OS), progression-free survival (PFS), and disease-specific survival (DSS) of the primary BAC group were poorer than those of both the UrAC and UCGD groups (P=0.0046,P<0.0001,P=0.0077 respectively). Regarding BAC, patients with mucinous adenocarcinoma tended to have better OS and PFS than those with other histological types (P<0.005,P=0.0245). Multivariate Cox regression analysis revealed that tumor type (=0.002), T stage (=0.034), and the age-adjusted Charlson Comorbidity Index (aCCI) scores (=0.005) predicted the postoperative OS and DSS of the patients. For PFS, the tumor type (=0.011), grade (=0.000), and aCCI (=0.002) scores were predictive.

CONCLUSION

Among UrAC, primary BAC, and UCGD patients, the prognosis was poorest for those with primary BAC. Attempts should be made to diagnose these aggressive tumors early, since patients in whom tumors are detected early appear to survive longer.

摘要

目的

探讨人口统计学和病理特征对中国脐尿管腺癌(UrAC)、原发性膀胱腺癌(BAC)和伴腺性分化的尿路上皮癌(UCGD)生存结局的意义。

材料与方法

我们回顾性分析了非远处转移(≤T4M0)的病例。106例患者中,分别有30例(28.3%)、40例(37.7%)和36例(34.0%)符合UrAC、原发性BAC和UCGD的标准。收集了患者人口统计学、肿瘤病理学和生存结局的数据。中位随访时间为36个月。采用多因素Cox回归分析生存情况。

结果

UrAC患者(51.87±15.25岁)比原发性BAC患者(60.50±12.56岁)和UCGD患者(63.83±11.60岁)年轻(<0.001)。UrAC患者最可能处于T3 - 4期(70.0% >40.0% >44.4%;<0.001),而原发性BAC组的低分化率高于UrAC组和UCGD组(57.4% >18.5% >24.1%;<0.001)。Kaplan - Meier曲线显示,原发性BAC组的总生存(OS)、无进展生存(PFS)和疾病特异性生存(DSS)均比UrAC组和UCGD组差(分别为P = 0.0046、P < 0.0001、P = 0.0077)。对于BAC,黏液腺癌患者的OS和PFS往往优于其他组织学类型的患者(P < 0.005,P = 0.0245)。多因素Cox回归分析显示,肿瘤类型(= 0.002)、T分期(= 0.034)和年龄校正的Charlson合并症指数(aCCI)评分(= 0.005)可预测患者术后的OS和DSS。对于PFS,肿瘤类型(= 0.011)、分级(= 0.000)和aCCI(= 0.002)评分具有预测价值。

结论

在UrAC、原发性BAC和UCGD患者中,原发性BAC患者的预后最差。应努力早期诊断这些侵袭性肿瘤,因为早期发现肿瘤的患者似乎生存时间更长。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d0a3/9133414/74b72ee20310/fonc-12-860133-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验